- Trials with a EudraCT protocol (803)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
803 result(s) found for: phase II trials.
Displaying page 1 of 41.
EudraCT Number: 2018-003691-12 | Sponsor Protocol Number: TUD-CIRC01-071 | Start Date*: 2019-12-04 | ||||||||||||||||
Sponsor Name:Technische Universität Dresden | ||||||||||||||||||
Full Title: Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217 | ||||||||||||||||||
Medical condition: Colon cancer stage II | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003595-38 | Sponsor Protocol Number: AT845-01 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:Audentes Therapeutics, Inc. | |||||||||||||
Full Title: FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Di... | |||||||||||||
Medical condition: Late Onset Pompe Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002295-41 | Sponsor Protocol Number: PR2100 | Start Date*: 2009-01-29 |
Sponsor Name:The University of Birmingham | ||
Full Title: A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolo... | ||
Medical condition: Hormone refractory Prostate Cancer (HRPC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005164-15 | Sponsor Protocol Number: ALTERNATIVE | Start Date*: 2015-12-22 | |||||||||||||||||||||
Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III | |||||||||||||||||||||||
Full Title: A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients... | |||||||||||||||||||||||
Medical condition: Stage II - IV follicular lymphoma grade 1 - 3a and a high tumor burden not previously treated | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001283-30 | Sponsor Protocol Number: SPK-3006-101 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Spark Therapeutics | |||||||||||||
Full Title: Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease | |||||||||||||
Medical condition: Pompe Disease (also known as glycogen storage disease type II) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Trial now transitioned) NL (Ongoing) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000004-42 | Sponsor Protocol Number: C0993 | Start Date*: 2019-01-16 | |||||||||||
Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||
Full Title: TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC | |||||||||||||
Medical condition: Intermediate stage Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001356-37 | Sponsor Protocol Number: NSGO-CC-0304 | Start Date*: 2004-09-10 |
Sponsor Name:Nordic Society for Gynecological Cancer | ||
Full Title: Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer | ||
Medical condition: Metastatic or recurrent cervical cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005200-35 | Sponsor Protocol Number: DNLI-E-0007 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Denali Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp (DNL310) vs Idursulfase in Pediatric and Young Adults Participants With Neuronopathic ... | |||||||||||||
Medical condition: Mucopolysaccharidosis Type II [MPS II] | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001598-10 | Sponsor Protocol Number: UCL/12/0158 | Start Date*: 2012-12-21 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A phase I/II study of first line Ganetespib with pemetrexed/cisplatin, in patients with malignant pleural mesothelioma | |||||||||||||
Medical condition: Malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004946-83 | Sponsor Protocol Number: BR.31 | Start Date*: 2015-02-19 | |||||||||||||||||||||
Sponsor Name:Clinipace GLobal Ltd. | |||||||||||||||||||||||
Full Title: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer | |||||||||||||||||||||||
Medical condition: Completely resected non-small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001250-40 | Sponsor Protocol Number: ICORG07-01 | Start Date*: 2008-08-18 | |||||||||||
Sponsor Name:Cancer Trials Ireland | |||||||||||||
Full Title: An open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide, And Rituximab in Patients with Chronic Lymphocytic Leukaemia who are Newly Diagnosed, ha... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005761-11 | Sponsor Protocol Number: AG0501CR | Start Date*: 2006-05-25 |
Sponsor Name:Australasian Gastro−Intestinal Trials Group | ||
Full Title: The MAX study: A randomised phase II/III study to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer | ||
Medical condition: Previously untreated metastatic colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024264-18 | Sponsor Protocol Number: MT103-205 | Start Date*: 2011-11-23 | |||||||||||
Sponsor Name:Amgen Research (Munich) GmbH | |||||||||||||
Full Title: A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Pati... | |||||||||||||
Medical condition: Pediatric and adolescent patients with B-precursor ALL in second or later bone marrow relapse, in any marrow relapse after allogeneic HSCT, or refractory to other treatments. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) NL (Completed) IT (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003005-25 | Sponsor Protocol Number: RADIANCE | Start Date*: 2019-12-17 | ||||||||||||||||
Sponsor Name:University Hospital Frankfurt, Goethe University | ||||||||||||||||||
Full Title: Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal Cancer Study Group | ||||||||||||||||||
Medical condition: anal cancer (UICC-Stage IIB-IIIC, incl. T2>4cm Nany ) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005621-55 | Sponsor Protocol Number: 99010206E | Start Date*: 2006-06-14 | |||||||||||
Sponsor Name:Zeria Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: Z-338:A Phase IIb, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety in Subjects with Functional Dyspepsia | |||||||||||||
Medical condition: Functional Dyspepsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) GB (Completed) BE (Completed) HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001278-26 | Sponsor Protocol Number: VEG102857 | Start Date*: 2006-10-31 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma | ||
Medical condition: Relaped Malignant Glioma = patients with anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, glioblastoma multiforme or gliosarcoma at recurrence | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022754-17 | Sponsor Protocol Number: UCL/09/0176 | Start Date*: 2012-08-22 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Bevacizumab And Combination Chemotherapy in rectal cancer Until Surgery: A Phase II, Multicentre, Open-label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defin... | ||||||||||||||||||
Medical condition: Locally advanced rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000381-36 | Sponsor Protocol Number: 26083 | Start Date*: 2006-04-26 |
Sponsor Name:University of Nottingham | ||
Full Title: Randomised controlled trials to investigate whether prophylactic antibiotics can prevent further episodes of cellulitis (erysipelas) of the leg (PATCH I & PATCH II) | ||
Medical condition: Cellulitis of the leg | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001914-41 | Sponsor Protocol Number: AL1201AV | Start Date*: 2012-10-19 | ||||||||||||||||
Sponsor Name:Allergopharma Joachim Ganzer KG | ||||||||||||||||||
Full Title: Open label phase II multicentre clinical trial to evaluate safety during shortened uptitration of an allergoid grass pollen preparation in adult patients with IgE mediated allergic rhinitis / rhino... | ||||||||||||||||||
Medical condition: ICD classificationcode: J 45.0 and J30.1 Patients with IgE mediated allergic rhinitis / rhinoconjunctivitis with or without controlled bronchial asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003013-34 | Sponsor Protocol Number: UOL0730 | Start Date*: 2020-03-02 | ||||||||||||||||||||||||||
Sponsor Name:University of Leicester | ||||||||||||||||||||||||||||
Full Title: Beyond Allergic Th2 Severe Asthma | ||||||||||||||||||||||||||||
Medical condition: T2-High and T2-Low severe asthma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
